The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer.
The time taken to obtain the results of BRCA1/2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being.
The main objective of this project is to compare the results obtained with an ultra-fast kit developed by O.N.T with those obtained with the current gold standard, NGS sequencing.
Age ≥ 18 years
Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer.
The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.
Diagnosis of the disease ≤ 6 months
Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires
Patients who do not have an email address and/or do not have internet access or tools to connect to the internet
Women who are pregnant, may become pregnant or are breast-feeding
Persons deprived of their liberty or under guardianship (including curatorship)